Himanshu Mishra’s Post

https://lnkd.in/gbdeS3RE As important a paper, in Journal of Clinical Oncology, in recent years in the field of #ocularoncology and #ocularmelanoma was just brought forth by the Collaborative Ocular Oncology Group, lead by J William Harbour, MD at UT Southwestern. A multi-country effort that has now validated gene expression profiling as well as PRAME, as a risk modifier, in a very clinically relevant patient population. With over 1500 patients followed for over 42 months, a new 4 group stratification predicts melanoma-specific survival at 98.8% for the lowest risk compared to 61% for the highest risk groups. This information will inform clinicians, patients, and - most importantly- clinical trial entry into the future. National Cancer Institute (NCI), Castle Biosciences, Inc.Byers Eye Institute at Stanford, American Society of Clinical Oncology (ASCO), Journal of Clinical Oncology, Zelia Correa, Amy Schefler, Miguel Materin, Thomas Aaberg Jr, Alison Skillet, Ezekiel Weis, Ivana Kim, Scott Walter, Brian Marr, Basil Williams, Scott Oliver, James Dollar, Song Zhang, Tony Tsai, David Reichstein, @eugene Shildkrot, @devron char, Demirci Hakan, @Cameron javid, @dan gomobos, JayPeter Hovland, Christina D.,

Veracyte, Inc. #Prostate #Decipher Prostate Genomic Classifier #NCCN Guidelines --Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines --The new NCCN Guidelines classify the Decipher Prostate test as Level 1B according to the “Simon Criteria,” which are published criteria for assigning a level of evidence for clinical biomarkers based on the quality and quantity of evidence available. NCCN summarizes the treatment implications for patients based on their Decipher score and the published evidence from analyses of multiple randomized, phase 3 clinical trials. https://lnkd.in/gV-BvR4P

Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic #stockmarket #stocks #investing #businessnews #trading #daytrading #clinicaltrial #AI #artificialintelligence

Next-generation-sequencing-based homologous recombination deficiency (HRD) assay based on QIAGEN’s QIAseq xHYB technology, QIAGEN Digitial Insight solutions, and Myriad’s proprietary, FDA-approved MyChoice CDx® biomarkers #pharma #diagnostics #ngs #oncology #cancer #pathology

Labcorp's most recent research, presented at the 2024 SGO Annual Meeting, highlights the crucial role of biomarker testing in guiding personalized treatments for epithelial ovarian cancer. Genomic profiling is transforming patient care, ensuring better patient outcomes through tailored therapies #precisionmedicine #cancerdiagnostics #biotouch https://hubs.li/Q02pYm3c0

The word "innovative" is sometimes thrown around casually, but we love being able to back it up. In case you missed it, check out our paper co-authored with the Saha lab at the University of Wisconsin-Madison. Inspired by the Saha lab’s commitment to advancing gene-edited cell therapies, this work aims to remove the need for AAV, which is a significant bottleneck for therapeutic manufacturing. Combined with our CRISPR expertise, the team was able to both multiplex edits and optimize editing to balance high editing and knock-in rates with low off-target effects (and do it without the use of viral vectors). 🎯🎯🎯 Check out the article here: https://hubs.la/Q02zrPbJ0 #CARTtherapies #oncology #CRISPR #EditCoBio

“For the longest time, people thought this is not something that can be commercialized.” Chantale Bernatchez, head of Process Development at CTMC / A joint venture between Resilience + MD Anderson Cancer Center The FDA has recently approved Iovance Biotherapeutics’ tumor infiltrating lymphocyte (TIL) therapy Amtagvi® for patients with unresectable or metastatic melanoma – marking the first cell therapy of its class to target a solid tumor. In an interview with Labiotech.eu, Chantale shared her insights into TIL therapy and what the first approval means for the cell and gene therapy sector. As Amtagvi® paves the way for many more TIL therapy approvals, it is imperative that logistical and reimbursement challenges are overcome, so that these therapies are not just approvable but accessible and affordable too. Read more ➡️ https://lnkd.in/dDBfZ5PU #CellTherapy #GeneTherapy #Biotechnology #ManufacturingBrighterFutures #AdvancedTherapies

The level of evidence continues to build.

New publication shows Comprehensive Genomic Profilling (CGP), when compared to small panels, improves detection of actionable biomarkers and greater use of matched therapies, both of which were associated with significant increases in survival in patients with Advanced Non–Small Cell Lung Cancer (aNSCLC). Therefore, broadening the access and uptake of CGP testing enabling patients to receive molecularly driven precision therapies is paramount to improving outcomes in patients with aNSCLC. https://lnkd.in/dxpgc4zg

In case you missed the work published by Mary K Nesline et al. last week published in Oncology and Therapy... The Labcorp Oncology medical affairs team examined the downstream effect of single-gene testing for guideline-recommended biomarkers on comprehensive genomic profiling in non–small cell lung cancer (NSCLC). “Our findings have significant implications for patients with NSCLC...Undertesting and incomplete testing for oncogenic driver mutations can lead not only to underutilization of frontline targeted therapy, but also to improper use of upfront immune checkpoint inhibitors in patients with actionable genomic variants who can derive clinically meaningful benefits from biomarker-driven targeted therapy.” Bottomline: CGP should be performed on every advanced and metastatic NSCLC tumor. Want to read more? https://lnkd.in/eQebDqeS Vivek Subbiah, MD Kyle Strickland Heidi Ko, DO Paul DePietro Maureen Cooper Nini Wu, MD Jeffrey Conroy Sarabjot Pabla Zachary Wallen, PhD Pratheesh Sathyan PhD Kamal S. Saini Marcia Eisenberg Brian Caveney Eric Severson Shakti Ramkissoon